^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NRF2 activator

    Related drugs:
    1d
    Dimethyl fumarate as a promising therapeutic candidate for virus-associated myelopathy. (PubMed, Brain)
    A reduction in PVL was also observed in a subset of ex vivo PBMC cultures derived from individuals with HAM/TSP exhibiting high viral proliferative activity. These results suggest that DMF suppresses pathogenic immune activation in HAM/TSP and may therefore represent a promising therapeutic candidate for this disabling neuroinflammatory disorder.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    2d
    LADIGAGA: Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy (clinicaltrials.gov)
    P2, N=90, Recruiting, Assistance Publique - Hôpitaux de Paris | N=60 --> 90 | Trial completion date: Oct 2027 --> Apr 2029 | Trial primary completion date: Oct 2025 --> Apr 2027
    Enrollment change • Trial completion date • Trial primary completion date
    2d
    CHOC-LATE: A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (clinicaltrials.gov)
    P3, N=316, Not yet recruiting, Tata Memorial Hospital | Initiation date: Sep 2025 --> Mar 2026
    Trial initiation date
    14d
    A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia (clinicaltrials.gov)
    P2, N=172, Completed, Biogen | Active, not recruiting --> Completed
    Trial completion
    |
    Skyclarys (omaveloxolone)
    23d
    A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
    P2, N=127, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting | N=275 --> 127
    Enrollment closed • Enrollment change
    25d
    The Role of Iron-Overloaded Macrophages in Mesenchymal Stem Cell Senescence and Anemia in Myelodysplastic Syndromes: Protocol for an In Vitro Study. (PubMed, JMIR Res Protoc)
    This study is expected to elucidate a novel molecular mechanism linking iron overload in macrophages to BMSC dysfunction and anemia in MDS. The findings could identify the Keap1-Nrf2-ARE pathway as a potential therapeutic target for managing MDS-related anemia.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • CD68 (CD68 Molecule) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    28d
    A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 (clinicaltrials.gov)
    P1, N=70, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Skyclarys (omaveloxolone)
    1m
    A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (clinicaltrials.gov)
    P1, N=35, Recruiting, Biogen | Trial completion date: Feb 2030 --> Nov 2030
    Trial completion date
    |
    Skyclarys (omaveloxolone)
    1m
    pH-triggered Mn-ZIF8 nanoreactor enhances tumor immunotherapy by amplifying the cGAS-STING pathway through a self-reinforcing gas-metal synergy strategy. (PubMed, J Nanobiotechnology)
    In this study, we propose a Gas-Metal Synergy Strategy, which integrates immune activation and biosafety, by engineering a pH-responsive manganese-based zeolitic imidazolate framework (named MRPH) nanoplatform co-loaded with the nitric oxide (NO) donor RRX-001...Both in vitro and in vivo studies demonstrate that MRPH significantly enhances gas-amplified metalloimmunotherapy. This work pioneers a low-toxicity paradigm that integrates gas therapy and metal-based immunotherapy, offering a transformative approach to solid tumor immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    nibrozetone (RRx-001)
    1m
    Effects of the Pharmacological Modulation of NRF2 in Cancer Progression. (PubMed, Medicina (Kaunas))
    In contrast, NRF2 activators, such as bardoxolone methyl (CDDO-Me), sulforaphane, and dimethyl fumarate, exhibit chemopreventive effects by enhancing detoxification and mitigating oxidative DNA damage during early tumorigenesis...Therefore, understanding the temporal and contextual effects of NRF2 signaling is crucial for therapeutic design. The aim of this review is to examine how pharmacological modulation of NRF2 influences the invasive and metastatic dimensions of tumor progression, in addition to discussing its potential integration into TNM-based prognostic and treatment frameworks.
    Review • Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    1m
    Synthetic Oleanane Triterpenoids Reduce Tumor Growth and Promote an Anti-Tumor Immune Response Independent of Cancer KEAP1 Mutational Status. (PubMed, Antioxidants (Basel))
    Similarly, subcutaneous KEAP1 KO tumors were larger and more immune-suppressed compared to WT tumors. Both CDDO-Me and omaveloxolone reduced the tumor burden and improved immune cell phenotypes within the TIME independent of KEAP1 mutational status.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KEAP1 mutation
    |
    Skyclarys (omaveloxolone)
    2ms
    A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Biogen
    New P1 trial
    |
    Skyclarys (omaveloxolone)